Fig. 4From: Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patientsComparisons of the ROC curves for endpoint PFS9 prediction of response of the baseline (a), delta (b), and longitudinal RF models (c) based on clinical, radiomics, or deep-radiomics dataBack to article page